HBW Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

YSL Beauté

This article was originally published in The Rose Sheet

Executive Summary

Maggie Ciafardini tapped as CEO and general manager for YSL Beauté U.S. subsidiary, company announces. Effective in early April, Ciafardini will join the firm from Beauté Prestige International, where she has worked since 1999, serving most recently as exec VP and general manager. While at BPI, Ciafardini oversaw fragrance brands such as Jean Paul Gaultier and Issey Miyake, while adding new licenses like Narciso Rodriguez. Exec will succeed Alain Denoly, who has held the post of CEO since 2001. YSL Beauté Chairman and CEO Chantal Roos also is a BPI alum, having worked as president and CEO before rejoining YSL in 2000...

You may also be interested in...



New EU Filings

Obecabtagene autoleucel, Autolus Therapeutics’s investigational treatment for relapsed or refractory B cell precursor acute lymphoblastic leukemia, is among the latest products that have been filed for review by the European Medicines Agency for potential EU marketing approval.

P&G Restores Volume Growth In Beauty, Grooming After Pricing Run

Procter & Gamble reports strong consumer spending in the US and Europe after a 3% increase in product pricing over the past year. Dragging on fiscal third-quarter results, sales of SK-II in China fell 30% for the January-March period, while lower incidence of cough and cold impacted Health Care performance.

BMS Has A Strong Pipeline, But Access Challenges Remain

Bristol Myers Squibb’s head of major markets, Monica Shaw, wants to improve patients’ access to lifesaving therapies. And the group has several new products ready to roll.

Latest Headlines
See All
UsernamePublicRestriction

Register

RS011961

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel